Physician profile
Charisma Pinna
NPI 1134182264
$3,433.22
in general payments reported to CMS, 2019-2025
18 companies · $519 in 2025
The $519 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $727 · 2021: $741 · 2022: $347 · 2023: $468 · 2024: $476 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438 · Consulting Fee: $25.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.98 |
| Consulting Fee | $25.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $510.83 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $456.81 | 2020-2025 | Haegarda, Hizentra, Andembry |
| Astrazeneca Pharmaceuticals LP | $448.09 | 2019-2023 | Tezspire |
| Genzyme Corporation | $446.97 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $375.33 | 2020-2024 | Hyqvia, Cuvitru, Gammagard |
| Regeneron Healthcare Solutions, INC. | $225.41 | 2020-2025 | Dupixent |
| Genentech USA, INC. | $188.21 | 2019-2025 | Xolair |
| Amgen INC. | $134.95 | 2022-2025 | Tezspire |
| Optinose US, INC. | $131.31 | 2022-2025 | |
| Glaxosmithkline, LLC. | $125.59 | 2021-2023 | Trelegy Ellipta |
| Octapharma USA, INC. | $103.99 | 2020-2021 | |
| Pfizer INC. | $77.58 | 2021 | |
| Biocryst US Sales Co., LLC | $68.29 | 2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $39.28 | 2020 | |
| Blueprint Medicines Corporation | $30.91 | 2025 | Ayvakit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $25.98 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $22.27 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $21.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charisma Pinna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.